140 related articles for article (PubMed ID: 20371457)
1. PPARgamma activation: a potential treatment for pulmonary hypertension.
Hansmann G; Zamanian RT
Sci Transl Med; 2009 Dec; 1(12):12ps14. PubMed ID: 20371457
[TBL] [Abstract][Full Text] [Related]
2. PPARgamma and the pathobiology of pulmonary arterial hypertension.
Rabinovitch M
Adv Exp Med Biol; 2010; 661():447-58. PubMed ID: 20204748
[TBL] [Abstract][Full Text] [Related]
3. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Chetty VT; Sharma AM
Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.
Hansmann G; Wagner RA; Schellong S; Perez VA; Urashima T; Wang L; Sheikh AY; Suen RS; Stewart DJ; Rabinovitch M
Circulation; 2007 Mar; 115(10):1275-84. PubMed ID: 17339547
[TBL] [Abstract][Full Text] [Related]
5. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.
Hansmann G; de Jesus Perez VA; Alastalo TP; Alvira CM; Guignabert C; Bekker JM; Schellong S; Urashima T; Wang L; Morrell NW; Rabinovitch M
J Clin Invest; 2008 May; 118(5):1846-57. PubMed ID: 18382765
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
7. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
El Midaoui A; Wu L; Wang R; de Champlain J
Am J Hypertens; 2006 Apr; 19(4):407-12. PubMed ID: 16580578
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-γ ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor.
Liu Y; Tian XY; Mao G; Fang X; Fung ML; Shyy JY; Huang Y; Wang N
Hypertension; 2012 Dec; 60(6):1471-8. PubMed ID: 23108648
[TBL] [Abstract][Full Text] [Related]
9. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
Dobrian AD
Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756
[TBL] [Abstract][Full Text] [Related]
10. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
Towfighi A; Ovbiagele B
Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
[TBL] [Abstract][Full Text] [Related]
11. Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?
Bouskila M; Pajvani UB; Scherer PE
Int J Obes (Lond); 2005 Mar; 29 Suppl 1():S17-23. PubMed ID: 15711577
[TBL] [Abstract][Full Text] [Related]
12. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
[TBL] [Abstract][Full Text] [Related]
13. [Novel concepts in the pathobiology of pulmonary arterial hypertension].
Rosenkranz S
Dtsch Med Wochenschr; 2008 Oct; 133 Suppl 6():S167-9. PubMed ID: 18814087
[TBL] [Abstract][Full Text] [Related]
14. [Genetics and physiopathology of primary or secondary pulmonary artery hypertension].
Adnot S; Eddahibi S
Bull Acad Natl Med; 2003; 187(8):1529-42; discussion 1543-5. PubMed ID: 15146583
[TBL] [Abstract][Full Text] [Related]
15. Activation of the Metabolic Master Regulator PPARγ: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.
Hansmann G; Calvier L; Risbano MG; Chan SY
Am J Respir Cell Mol Biol; 2020 Feb; 62(2):143-156. PubMed ID: 31577451
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance.
Guo L; Tabrizchi R
Pharmacol Ther; 2006 Jul; 111(1):145-73. PubMed ID: 16305809
[TBL] [Abstract][Full Text] [Related]
17. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells.
Ogawa D; Nomiyama T; Nakamachi T; Heywood EB; Stone JF; Berger JP; Law RE; Bruemmer D
Circ Res; 2006 Apr; 98(7):e50-9. PubMed ID: 16556873
[TBL] [Abstract][Full Text] [Related]
18. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
19. Receptor for activated C-kinase 1, a novel interaction partner of type II bone morphogenetic protein receptor, regulates smooth muscle cell proliferation in pulmonary arterial hypertension.
Zakrzewicz A; Hecker M; Marsh LM; Kwapiszewska G; Nejman B; Long L; Seeger W; Schermuly RT; Morrell NW; Morty RE; Eickelberg O
Circulation; 2007 Jun; 115(23):2957-68. PubMed ID: 17515463
[TBL] [Abstract][Full Text] [Related]
20. Mutations in bone morphogenetic protein type II receptor cause dysregulation of Id gene expression in pulmonary artery smooth muscle cells: implications for familial pulmonary arterial hypertension.
Yang J; Davies RJ; Southwood M; Long L; Yang X; Sobolewski A; Upton PD; Trembath RC; Morrell NW
Circ Res; 2008 May; 102(10):1212-21. PubMed ID: 18436795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
